Registration Dossier

Diss Factsheets

Administrative data

Description of key information

In a 90-day oral repeated dose toxicity study with rats, conducted according to OECD/EC guidelines and GLP principles, abnormalities in estrous cycle (coinciding with microscopic alterations in ovaries and/or uterus and/or vagina) were observed in females dosed at 300 mg/kg bw/day. In males, increased incidence and severity of hypertrophy/hyperplasia of the follicular cells of the thyroid glands were found at 1000 mg/kg bw/day.

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
NOAEL
100 mg/kg bw/day
Study duration:
subchronic
Species:
rat
Quality of whole database:
The study was performed according to OECD/EC guidelines and GLP principles (Klimisch 1 study).
System:
female reproductive system
Organ:
ovary
uterus
vagina

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Justification for classification or non-classification

The observed adverse effects in a subchronic oral toxicity study, namely irregular estrous cycle and the reduction in corpora lutea, accompanied by the delay in fetal development, mandate a classification of CXN1-55 as reproductive toxicant category 2 according to Regulation (EC) No. 1272/2008. The substance is not further classified for repeated dose toxicity.